I did some reading today and think I have found th
Post# of 72440
(Total Views: 359)
Posted On: 02/25/2020 6:14:52 PM
I did some reading today and think I have found the rationale for Brilacidin investigation since it isn’t an antiviral.
Looks like it may be to treat the secondary bacterial lung infections:
Brillacidin for Corona Virus
. Perspective of Use of Antiviral Peptides against Influenza Virus
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...s-07-02883
o Considering the fact that viral infection is often followed by
secondary bacterial infections [17], it would be highly advantageous if
peptide therapy can target both the primary viral and a secondary bacterial
infection. There is a possibility of complementing treatment of standard
antiviral drugs with antibacterial drugs, such as neuraminidase inhibitors
(oral oseltamivir and inhaled zanamivir) or M2 ion channel blockers
(amantadine and rimantadine). The synergic effect and immune-modulatory role
of such drug combinations have not been studied yet in protection against
potential secondary bacterial infection.
. Secondary Bacterial Infections in Patients with Seasonal Influenza A
and Pandemic H1N1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705841/
o During previous influenza pandemics, secondary bacterial infections
caused by Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus
aureus, and Streptococcus pyogenes have been important contributors to
morbidity and mortality [4, 7, 8]. The information on the epidemiology of
secondary bacterial infections might, therefore, play a significant role in
reducing mortality and morbidity rates due to influenza by early
implementation of accurate empiric antibacterial therapy.
. New and alternative approaches to tackling antibiotic resistance
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854692/
o A related compound-a defensin-mimetic, brilacidin (PMX-30063)-was
under development by PolyMedix, these assets have been acquired by
Cellceutix, Beverly, MA, USA in September 2013. This molecule was shown to
have activity against S. aureus, Enterococcus faecium as well as
Gram-negative species, for example E. coli.
Looks like it may be to treat the secondary bacterial lung infections:
Brillacidin for Corona Virus
. Perspective of Use of Antiviral Peptides against Influenza Virus
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...s-07-02883
o Considering the fact that viral infection is often followed by
secondary bacterial infections [17], it would be highly advantageous if
peptide therapy can target both the primary viral and a secondary bacterial
infection. There is a possibility of complementing treatment of standard
antiviral drugs with antibacterial drugs, such as neuraminidase inhibitors
(oral oseltamivir and inhaled zanamivir) or M2 ion channel blockers
(amantadine and rimantadine). The synergic effect and immune-modulatory role
of such drug combinations have not been studied yet in protection against
potential secondary bacterial infection.
. Secondary Bacterial Infections in Patients with Seasonal Influenza A
and Pandemic H1N1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705841/
o During previous influenza pandemics, secondary bacterial infections
caused by Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus
aureus, and Streptococcus pyogenes have been important contributors to
morbidity and mortality [4, 7, 8]. The information on the epidemiology of
secondary bacterial infections might, therefore, play a significant role in
reducing mortality and morbidity rates due to influenza by early
implementation of accurate empiric antibacterial therapy.
. New and alternative approaches to tackling antibiotic resistance
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854692/
o A related compound-a defensin-mimetic, brilacidin (PMX-30063)-was
under development by PolyMedix, these assets have been acquired by
Cellceutix, Beverly, MA, USA in September 2013. This molecule was shown to
have activity against S. aureus, Enterococcus faecium as well as
Gram-negative species, for example E. coli.
(11)
(1)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
***On 02/26/2016 at 8:33 am Scottsmith admited to posting under 5 aliases but his post was subsequently deleted. I have a screen shot and will email it to anyone interested.
Scroll down for more posts ▼